NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
Clinical Trials
9 trialsNCT07407452 2026-02-12
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Not yet recruiting
NCT05128734 2025-12-15
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
AHS Cancer Control Alberta
Phase 2 Not yet recruiting
NCT05522491 2025-12-11
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT07187674 2025-09-23
The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
Harbin Medical University
Phase NA Not yet recruiting
NCT07113964 2025-08-11
QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT07090369 2025-07-29
LumOnate
Peter MacCallum Cancer Centre, Australia
Phase 1 Not yet recruiting
NCT07005583 2025-06-05
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06650709 2024-10-23
NEOCATS
British Columbia Cancer Agency
Phase 2 Not yet recruiting